Additionally, we established a nomogram that integrates PD-L2 with clinicopathological factors (age, grade, and IDH mutation status) and discovered that it performs exceptionally well in predicting 1-, 3-, and 5-year OS in glioma patients. This evidence concerns the gene PDCD1LG2 and glioma.